TNYA Stock Overview
A biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tenaya Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.94 |
| 52 Week High | US$7.01 |
| 52 Week Low | US$1.66 |
| Beta | 2.39 |
| 11 Month Change | -33.10% |
| 3 Month Change | -34.01% |
| 1 Year Change | -28.41% |
| 33 Year Change | -90.31% |
| 5 Year Change | n/a |
| Change since IPO | -87.36% |
Recent News & Updates
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Sep 18
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
Jun 04Recent updates
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Sep 18We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
Jun 04Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Dec 20Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?
Aug 08Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely
Mar 07Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?
Dec 06Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment
Sep 06Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07
Aug 10Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?
Aug 08We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely
Mar 03Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth
Nov 01Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms
Aug 06Shareholder Returns
| TNYA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.0% | -3.8% | 1.8% |
| 1Y | -28.4% | 16.5% | 31.9% |
Return vs Industry: TNYA underperformed the US Biotechs industry which returned 18.7% over the past year.
Return vs Market: TNYA underperformed the US Market which returned 32.8% over the past year.
Price Volatility
| TNYA volatility | |
|---|---|
| TNYA Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TNYA's share price has been volatile over the past 3 months.
Volatility Over Time: TNYA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 140 | Faraz Ali | www.tenayatherapeutics.com |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
Tenaya Therapeutics, Inc. Fundamentals Summary
| TNYA fundamental statistics | |
|---|---|
| Market cap | US$155.41m |
| Earnings (TTM) | -US$120.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs TNYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNYA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$120.74m |
| Earnings | -US$120.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TNYA perform over the long term?
See historical performance and comparison